Alzheimer's Diseases Risk Level Classifications Using Chaos Technique
This paper aim to classify Alzheimer's diseases risk level determining Dementia and Epilepsy which is a collective term used to describe the problems that people with various underlying brain disorders or damage can have with their memory, language and thinking. Alzheimer disease is the best known and most common disorder under the umbrella of Dementia and Epilepsy. Brain functions are measured in the hope of determining and differentiating certain functional conditions of the brain. The raw EEG signals are sampled and parameter like energy, variance, peaks, sharp and spikes waves, duration, events and covariance are detected. In this classification it provides a better way in diagnosis of Epilepsy as well as Dementia patients. It also aims to safeguard the patient’s life during the critical situations. The aim of this work is to investigate possible metabolic impairment within the thalamus in patients suffering from both focal (mesial temporal lobe epilepsy with hippocampus sclerosis) and generalized epilepsy and dementia resulting from brain damage using Chaos-Voxel.
Keywords: EEG signals, epilepsy risk levels, fuzzy logic, chaotic optimization, Elman neural network
Cite this Article Jagrati Srivastava, Pradeep Tomar. Alzheimer's Diseases Risk Level Classifications Using Chaos Technique. Journal of Software Engineering Tools & Technology Trends. 2015; 2(2): 36–46p.
Rullier L, Lagarde A, Bouisson J, et al. Psychosocial correlates of nutritional status of family care givers of persons with dementia. Int Psychogeriatr. 2014; 26: 105–113p.
Tsakos G, Herrick K, Sheiham A, et al. Edentulism and fruit and vegetable intake in low-income adults. J Dent Res. 2010; 89: 462–467p.
Yu YH, Kuo HK. Association between cognitive function and periodontal disease in older adults. J Am Geriatr Soc. 2008; 56: 1693–1697p.
Gil-Montoya JA, Ponce G, Sanchez Lara I, et al. Association of the oral health impact profile with malnutrition risk in Spanish elders. Arch Gerontol Geriatr. 2013; 57: 398–402p.
Furuta M, Komiya-Nonaka M, Akifusa S, et al. Interrelationship of oral health status, swallowing function, nutritional status, and cognitive ability with activities of daily living in Japanese elderly people receiving home care services due to physical disabilities. Community Dent Oral Epidemiol. 2013; 41: 173–181p.
Dion N, Cotart JL, Rabilloud M. Correction of nutrition test errors for more accurate quantification of the link between dental health and malnutrition. Nutrition. 2007; 23: 301–307p.
Cabre M, Serra-Prat M, Palomera E, et al. Prevalence and prognostic implications of dysphagia in elderly patients with pneumonia. Age Ageing. 2010; 39: 39–45p.
Van der Maarel-Wierink CD, Meijers JM, et al. Subjective dysphagia in older care home residents: A cross-sectional, multi-centre point prevalence measurement. Int J Nurs Stud. 2014; 51: 875–881p.
Alagiakrishnan K, Bhanji RA, Kurian M. Evaluation and management of oropharyngeal dysphagia in different types of dementia: a systematic review. Arch Gerontol Geriatr. 2013; 56: 1–9p.
Sura L, Madhavan A, Carnaby G, et al. Dysphagia in the elderly: management and nutritional considerations. ClinInterv Aging 2012; 7: 287–298p.
Vanderwee K, Clays E, Bocquaert I, et al. Malnutrition and associated factors in elderly hospital patients: a Belgian cross-sectional, multi-centre study. Clin Nutr. 2010; 29: 469–476p.
McCaddon A. Vitamin B12 in neurology and ageing; clinical and genetic aspects. Biochimie. 2013; 95: 1066–1076p.
Inada M, Toyoshima M, Kameyama M. Cobalamin contents of the brains in some clinical and pathologic states. Int J Vitam Nutr Res. 1982; 52: 423–429p.
Karnaze DS, Carmel R. Low serum cobalamin levels in primary degenerative dementia. Do some patients harbor a typical cobalamin deficiency states? Arch Intern Med.1987; 147: 429–431p.
Regland B, Gottfries CG, Oreland L, et al. Low B12 levels related to high activity of platelet MAO in patients with dementia disorders. A Retrospective Study Acta Psychiatr Scand. 1988; 78: 451–457p.
Renvall MJ, Spindler AA, Ramsdell JW, et al. Nutritional status of free-living Alzheimer’s patients. Am J Med Sci.1989; 298: 20–27p.
Ikeda T, Furukawa Y, Mashimoto S, et al. Vitamin B12 levels in serum and cerebrospinal fluid of people with Alzheimer’s disease. Acta Psychiatr Scand. 1990; 82: 327– 329p.
Nijst TQ, Wevers RA, Schoonderwaldt HC, et al.Vitamin B12 and folate concentrations in serum and cerebrospinal fluid of neurological patients with special reference to multiple sclerosis and dementia. J Neurol Neurosurg Psychiatry. 1990; 53: 951–954p.
Bottiglieri T, Godfrey P, Flynn T, et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry.1990; 53: 1096–1098p.
Joosten E, Lesaffre E, Riezler R, et al. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer’s disease? J Gerontol A Biol Sci Med Sci. 1997; 52: 76–79p.
McCaddon A, Davies G, Hudson P, et al.Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry.1998; 13: 235–239p.
Clarke R, Smith AD, Jobst KA, et al. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol .1998; 55: 1449–1455p.
Farkas M, Keskitalo S, Smith DE, et al. Hyperhomocysteinemia in Alzheimer’s disease: the hen and the egg? J Alzheimers Dis. 2013; 33: 1097–1104p.
Hinterberger M, Fischer P. Folate and Alzheimer: when time matters. J Neural Transm. 2013; 120: 211–224p.
Morris MS. The role of B vitamins in preventing and treating cognitive impairment and decline. Adv Nutr. 2012; 3: 801–812p.
Boucher BJ. The problems of vitamin D insufficiency in older people. Aging Dis. 2012; 3: 313–329p.
Zhao Y, Sun Y, Ji HF, et al. Vitamin D levels in Alzheimer’s and Parkinson’s diseases: a meta-analysis. Nutrition. 2013; 29: 828–832p.
Lu’o’ng KV, Nguyen LT. The role of vitamin D in Alzheimer’s disease: possible genetic and cellsignaling mechanisms. Am J Alzheimers Dis Other Demen. 2013; 28: 126–136p.
Lu’o’ng KV, Nguyen LT. The beneficial role of vitamin D in Alzheimer’s disease. Am J Alzheimers Dis Other Demen.2011; 26: 511–520p.
Annweiler C, Fantino B, Schott AM, et al. Vitamin D insufficiency mild cognitive impairment: cross-sectional association. Eur J Neurol. 2012; 19: 1023–1029p.
Peterson A, Mattek N, Clemons A, et al.Serum vitamin D concentrations are associated with falling and cognitive function in older adults. J Nutr Health Aging. 2012; 16: 898–901p.
Troesch B, Eggersdorfer M, Weber P. The role of vitamins in aging societies. Int J Vitam utr Res. 2012; 82: 355–359p.
Lopes da Silva S, Vellas B, Elemans S, et al. Plasma nutrient status of patients with Alzheimer’s disease: Systematic review and meta-analysis. Alzheimers Dement. 2014; 10: 485–502p.
Cardoso BR, Cominetti C, Cozzolino SM. Importance and management of micronutrient deficiencies in patients with Alzheimer’s disease. ClinInterv Aging. 2013; 8: 531–542p.
Volkert D, Berner YN, Berry E, et al. ESPEN guidelines on enteral nutrition: Geriatrics. Clin Nutr.2006; 25: 330–360p.
Allen VJ, Methven L, Gosney MA. Use of nutritional complete supplements in older adults with dementia: systematic review and meta-analysis of clinical outcomes. Clin Nutr . 2013; 32: 950–957p.
Allen VJ, Methven L, Gosney M. Impact of serving method on the consumption of nutritional supplement drinks: randomized trial in older adults with cognitive impairment. J Adv Nurs. 2014; 70: 1323–1333p.
Mendiratta P, Tilford JM, Prodhan P, et al. Trends in percutaneous endoscopic gastrostomy placement in the elderly from 1993 to 2003. Am J Alzheimers Dis Other Demen. 2012; 27: 609–613p.
Loser C, Aschl G, Hebuterne X, et al. ESPEN guidelines on artificial enteral nutrition--percutaneous endoscopic gastrostomy (PEG). Clin Nutr. 2005; 24: 848–861p.
Sobotka L, Schneider SM, Berner YN, et al. ESPEN Guidelines on Parenteral Nutrition: Geriatrics. Clin Nutr. 2009; 28: 461–466p.
Wu HS, Lin LC, Wu SC, et al. The effectiveness of spaced retrieval combined with Montessori-based activities in improving the eating ability of residents with dementia. J Adv Nurs. 2014; 70: 1891–1901p.
Alarcon G, Nashef L, Cross H, et al. Epilepsy (Oxford Specialist Handbooks in Neurology). Oxford: Oxford University Press; 2009. 43. Antelo RE, Stanilla JK, Martin-Llonch N. Myoclonic seizures and “leg folding” phenomena with clozapine therapy: Report of two cases. Biol Psychiatry. 1994; 36: 759–762p. 44. Atkinson JM, Douglas-Hall P, Fischetti C, et al. Outcome following clozapine discontinuation: A retrospective analysis. J Clin Psychiatry. 2007; 68: 1027–1030p. 45. Baker RW, Conley RR. Seizures during clozapine therapy. Am J Psychiatry. 1991; 148: 1265–1266p. 46. Begum M. Clozapine-induced stuttering, facial tics and myoclonic seizures: A case report. Aust NZ J Psychiatry. 2005; 39: 202p. 47. Berman H, Zalma A, Du Rand CJ, et al. Clozapine-induced myoclonic jerks and drop attacks. J Clin Psychiatry. 1992; 53: 329–330p.
Boachie A, McGinnity MGA. Use of clozapine in a mental handicap hospital-report of the first 17 patients. Ir J Psychol Med. 1997; 14: 16–19p. 49. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003; 60: 392–400p. 50. Chung SJ, Jeong SH, Ahn YM, et al. A retrospective study of clozapine and electroencephalographic abnormalities in schizophrenic patients. Prog Neuro-psychopharmacol Biol Psychiatry. 2002; 26: 139–144p. 51. Conca A, Beraus W, Konig P, et al. A case of pharmacokinetic interference in comedication of clozapine and valproic acid. Pharmacopsychiatry. 2000; 33: 234–235p. 52. Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology. 2005; 64: 955–960p.
Dhar R, Singh T, Charvan BS.Clozapine-induced dropattack and myoclonus. German J Psychiatry. 2008; 11: 29–31p. 54. Duggal HS, Jagadheesan K, Nizamie SH. Clozapine-induced stuttering and seizures. Am J Psychiatry. 2002; 159: 315p. 55. DuMortier G, Mahe V, Pons D, et al. Clonic seizure associated with high clozapine plasmalevel. J Neuropsychiatry Clin Neurosci. 2001; 13: 302–303p. 56. Dursun SM, McIntosh D, Milliken H. Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatry. 1999; 56: 950p. 57. Englisch S, Esser A, Enning F, et al. Augmentation with pregabalin in schizophrenia. J Clin Psychopharmacol. 2010; 30: 437–440p. 58. Facciola G, Avenoso A, Scordo MG, et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit. 1999; 21: 341–345p. 59. Foster R, Olajide D. A case of clozapine-induced tonic-clonic seizures managed with valproate: Implications for clinical care. J Psychopharmacol. 2005; 19: 93–96p. 60. Freudenreich O, Weiner RD, McEvoy JP. Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry. 1997; 42: 132–137p. 61. Funderburg LG, Vertrees JE, True JE, et al. Seizure following addition of erythromycin to clozapine treatment. Am J Psychiatry. 1994; 151: 1840–184p.
- There are currently no refbacks.
This site has been shifted to https://stmcomputers.stmjournals.com/